Tesamorelin
Stabilized GHRH analog studied in lipodystrophy and visceral-adiposity research models.
Tesamorelin is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.
Its published Certificate of Analysis (lot 00011/0011, analyzed September 3, 2026) is from AV Analytics, a third-party laboratory, and reports 99.79% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the full 44-amino-acid native sequence stabilized with a trans-hexenoic acid modification that protects it from rapid enzymatic cleavage. It acts on the pituitary GHRH receptor, driving pulsatile growth-hormone release that preserves the natural feedback architecture of the axis.
It carries one of the deeper research records in the GHRH family, including substantial human clinical literature around body-composition endpoints — which distinguishes it from most compounds in this catalog and makes it a frequent reference standard in GH-axis study designs.
Tesamorelin is often studied alongside ghrelin-receptor secretagogues like ipamorelin, since the two engage complementary receptors on the same axis. Supplied lyophilized, HPLC-verified per lot, for laboratory research.
Published research
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionFalutz J, et al. J Acquir Immune Defic Syndr. 2010.PubMed →
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIVFalutz J, et al. N Engl J Med. 2007.PubMed →